A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Summary

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.

Timeline

Start

2026-02-09

Primary completion

2028-02

Completion

2028-02

Drugs

Indications